Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

NCT03113266 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

370

Enrollment

OTHER

Sponsor class

Conditions

Bladder Urothelial Carcinoma

Interventions

BIOLOGICAL: humanized anti-PD-1 monoclonal antibody toripalimab

Sponsor

Shanghai Junshi Bioscience Co., Ltd.